Share Issue/Capital Change • Feb 28, 2019
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Disclosed inside information pursuant to article 17 Market Abuse Regulation (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.
No Keyword 28.02.2019
Vienna - Vienna, 28 February 2019. Marinomed Biotech AG announces that the greenshoe option from the IPO of 39,000 shares at the offer price of EUR 75 per share was fully exercised. Erste Group Bank AG, acting as stabilising manager, has not conducted any stabilisation activities since the initial listing of the Marinomed shares on 1 February 2019.
After exercising the greenshoe option and subject to the registration of the capital increase in the commercial register planned for next week, the share capital amounts to EUR 1,469,772, split into 1,469,772 voting shares, and the free float amounts to around 39%.
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at www.marinomed.com [http://www.marinomed.com/].
Further inquiry note: Eva Prieschl-Grassauer, PhD Chief Scientific Officer, Marinomed Veterinärplatz 1, 1210 Vienna, Austria Tel.: +43 (0)1 250 77 4460 E-mail: [email protected] http://www.marinomed.com
Roland Mayrl Managing Partner, Metrum Communications Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria Tel.: +43 (0) 1 504 69 87 331 E-mail: [email protected] http://www.metrum.at
end of announcement euro adhoc --------------------------------------------------------------------------------
| issuer: | Marinomed Biotech AG |
|---|---|
| Veterinärplatz 1 | |
| A-1210 Wien | |
| phone: | 0043250774460 |
| FAX: | 0043250774493 |
| mail: | [email protected] |
| WWW: | www.marinomed.com |
| ISIN: | ATMARINOMED6, AT0000A1WD52 |
| indexes: | |
| stockmarkets: Wien | |
| language: | English |
Aussendung übermittelt durch euro adhoc The European Investor Relations Service
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.